Nina Bhatt

Nina Bhatt specializes in cancer vaccine adjuvant formulation optimization, investigating how adjuvant composition, particle size, depot kinetics, and innate immune activation profile determine the magnitude and durability of anti-tumor immune responses generated by personalized neoantigen vaccines. Her work has identified optimal adjuvant combinations for neoantigen peptide vaccines that generate polyfunctional CD4+ and CD8+ T cell responses. She has developed standardized immunotoxicology protocols for evaluating adjuvant safety in cancer patients with compromised immune systems. Her adjuvant optimization platforms are being adopted by academic and industry cancer vaccine programs.